Sensus Healthcare (SRTS)
(Delayed Data from NSDQ)
$3.27 USD
-0.02 (-0.61%)
Updated Apr 22, 2024 11:49 AM ET
After-Market: $3.42 +0.15 (4.59%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.27 USD
-0.02 (-0.61%)
Updated Apr 22, 2024 11:49 AM ET
After-Market: $3.42 +0.15 (4.59%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks for February 12th
by Zacks Equity Research
MSGE, AZEK, XRX, AMSC and SRTS have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2023.
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 116.67% and 3.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen (INGN) Surges 12.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sensus Healthcare, Inc. (SRTS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 60% and 7.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare (SRTS) Expands Global Base With New Pact
by Zacks Equity Research
The agreement includes the distribution of Sensus Healthcare's (SRTS) SRT-100, SRT-100+ and SR-100 Vision systems, specifically designed for the treatment of non-melanoma skin cancer and keloids.
CVRx (CVRX) Surges 7.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
CVRx (CVRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -209.09% and 63.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 7.14% and 1.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 6.10% and 7.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Sensus Healthcare (SRTS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sensus Healthcare (SRTS) stock based on the movements in the options market lately.
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -34.62% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 6.77% and 1.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Sensus Healthcare, Inc. (SRTS) Have the Potential to Rally 81.12% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Sensus Healthcare, Inc. (SRTS) points to an 81.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 72.6% Upside in Sensus Healthcare, Inc. (SRTS): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 72.6% upside potential for Sensus Healthcare, Inc. (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Down 46.9% in 4 Weeks, Here's Why Sensus Healthcare, Inc. (SRTS) Looks Ripe for a Turnaround
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sensus Healthcare, Inc. (SRTS) Q3 Earnings Lag Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -8.33% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
SeaSpine Holdings (SPNE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -40% and 0.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Recent Price Trend in Sensus Healthcare, Inc. (SRTS) is Your Friend, Here's Why
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Edwards Lifesciences (EW) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.61% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights TransMedics, PROCEPT BioRobotics and Sensus Healthcare
by Zacks Equity Research
TransMedics, PROCEPT BioRobotics and Sensus Healthcare are part of the Zacks top Analyst Blog Highlights.
3 Resilient Medical Stocks to Watch as Rate Hikes Continue
by Indrajit Bandyopadhyay
Here we discuss three Medical-Instruments stocks - TMDX, PRCT & SRTS - that continued to grow in the first nine months of 2022 even though three Fed rate hikes dragged broader indices down.
EDAP TMS S.A. (EDAP) Moves 7.3% Higher: Will This Strength Last?
by Zacks Equity Research
EDAP TMS S.A. (EDAP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.